US 12,144,872 B1
Modified nanodelivery system and method for enhanced in vivo medical and preclinical imaging
Mandip Sachdeva, Tallahassee, FL (US); and Apurva Patel, Longwood, FL (US)
Assigned to Florida A&M University, Tallahassee, FL (US)
Filed by Florida A&M University, Tallahassee, FL (US)
Filed on Jul. 7, 2021, as Appl. No. 17/369,104.
Application 17/369,104 is a division of application No. 15/226,070, filed on Aug. 2, 2016, granted, now 11,090,394.
Application 15/226,070 is a continuation of application No. 13/851,610, filed on Mar. 27, 2013, abandoned.
Claims priority of provisional application 61/674,449, filed on Jul. 23, 2012.
Claims priority of provisional application 61/615,977, filed on Mar. 27, 2012.
Int. Cl. A61B 5/00 (2006.01); A61B 8/00 (2006.01); A61B 8/08 (2006.01); A61B 10/00 (2006.01); A61K 9/127 (2006.01); A61K 47/14 (2017.01); A61K 49/00 (2006.01)
CPC A61K 49/0084 (2013.01) [A61B 5/0071 (2013.01); A61B 8/481 (2013.01); A61K 9/1272 (2013.01); A61K 47/14 (2013.01); A61K 49/0032 (2013.01)] 8 Claims
 
1. A method of delivering an active substance or agent to a target within a subject for medical and preclinical imaging, comprising:
providing at least one nanoparticle to the subject wherein the at least one nanoparticle carrier comprising
about 700 mg of at least one solid phase lipid selected from the group consisting of propylene glycol palmitostearate, glyceryl palmitostearate, and combinations thereof;
about 330 mg of at least one liquid phase lipid or oil selected from the group consisting of caprylic/capric triglycerides, medium chain triglycerides, diethylene glycol monoethyl ether, and combinations thereof; and
about 480 μl of at least one surfactant selected from the group consisting of polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monooleate, and a combination thereof;
encapsulating an active pharmaceutical agent within the at least one nanoparticle;
encapsulating a luciferin within the at least one nanoparticle;
conjugating a target-honing molecule to a surface of the at least one nanoparticle to form a nanoparticle delivery system; and
administrating the nanoparticle delivery system to the subject;
wherein biofluorescence of the luciferin occurs as a steady release for up to about 4 hours after intravenous administration of the nanoparticle delivery system to the subject; and
wherein the biofluorescence of the luciferin is detectable in the subject for at least 24 hours after intravenous administration of the nanoparticle delivery system to the subject.